JP2016531546A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531546A5 JP2016531546A5 JP2016515415A JP2016515415A JP2016531546A5 JP 2016531546 A5 JP2016531546 A5 JP 2016531546A5 JP 2016515415 A JP2016515415 A JP 2016515415A JP 2016515415 A JP2016515415 A JP 2016515415A JP 2016531546 A5 JP2016531546 A5 JP 2016531546A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- seq
- amino acid
- sample
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 15
- 238000000034 method Methods 0.000 claims 12
- 150000001413 amino acids Chemical group 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 8
- 102000005927 Cysteine Proteases Human genes 0.000 claims 5
- 108010005843 Cysteine Proteases Proteins 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 3
- 108060003951 Immunoglobulin Proteins 0.000 claims 3
- 102000018358 immunoglobulin Human genes 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 claims 2
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 claims 2
- 235000001014 amino acid Nutrition 0.000 claims 2
- 238000004458 analytical method Methods 0.000 claims 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 229940122803 Vinca alkaloid Drugs 0.000 claims 1
- 108010044540 auristatin Proteins 0.000 claims 1
- 229930195731 calicheamicin Natural products 0.000 claims 1
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical compound C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 238000004128 high performance liquid chromatography Methods 0.000 claims 1
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 108010091748 peptide A Proteins 0.000 claims 1
- 230000004481 post-translational protein modification Effects 0.000 claims 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 claims 1
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1316744.0 | 2013-09-20 | ||
| GBGB1316744.0A GB201316744D0 (en) | 2013-09-20 | 2013-09-20 | Method |
| PCT/EP2014/069920 WO2015040125A1 (en) | 2013-09-20 | 2014-09-18 | A method for analysing a sample of immunoglobulin molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016531546A JP2016531546A (ja) | 2016-10-13 |
| JP2016531546A5 true JP2016531546A5 (OSRAM) | 2017-10-26 |
Family
ID=49553168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016515415A Withdrawn JP2016531546A (ja) | 2013-09-20 | 2014-09-18 | 免疫グロブリン分子試料を分析する方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20160231329A1 (OSRAM) |
| EP (1) | EP3047280A1 (OSRAM) |
| JP (1) | JP2016531546A (OSRAM) |
| KR (1) | KR20160079784A (OSRAM) |
| AU (1) | AU2014323081A1 (OSRAM) |
| CA (1) | CA2923704A1 (OSRAM) |
| GB (1) | GB201316744D0 (OSRAM) |
| SG (1) | SG11201602138VA (OSRAM) |
| WO (1) | WO2015040125A1 (OSRAM) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595057B2 (en) * | 2000-12-21 | 2009-09-29 | Id Biomedical Corporation | Streptococcus pyogenes antigens and corresponding DNA fragments |
| ES2861600T3 (es) | 2014-04-04 | 2021-10-06 | Mayo Found Medical Education & Res | Isotipaje de inmunoglobulinas usando masa molecular precisa |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US11209439B2 (en) | 2015-09-24 | 2021-12-28 | Mayo Foundation For Medical Education And Research | Identification of immunoglobulin free light chains by mass spectrometry |
| WO2017097918A1 (en) | 2015-12-09 | 2017-06-15 | F. Hoffmann-La Roche Ag | Method for determining the in vivo interaction mode |
| EP3387439B1 (en) | 2015-12-09 | 2020-02-26 | H. Hoffnabb-La Roche Ag | Direct affinity measurement of human igg1 binding multimeric antigens |
| US12006530B2 (en) * | 2016-02-04 | 2024-06-11 | Genovis Ab | Streptococcal proteases |
| CN109313200B (zh) * | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
| WO2018049001A1 (en) | 2016-09-07 | 2018-03-15 | Mayo Foundation For Medical Education And Research | Identification and monitoring of cleaved immunoglobulins by molecular mass |
| WO2018093868A1 (en) * | 2016-11-16 | 2018-05-24 | University Of Florida Research Foundation, Inc. | Immunoglobulin proteases, compositions, and uses thereof |
| IL270950B2 (en) | 2017-05-26 | 2025-06-01 | Genovis Ab | Tools for glycan analysis |
| US11946937B2 (en) | 2017-09-13 | 2024-04-02 | Mayo Foundation For Medical Education And Research | Identification and monitoring of apoptosis inhibitor of macrophage |
| WO2019055632A1 (en) | 2017-09-13 | 2019-03-21 | Mayo Foundation For Medical Education And Research | IDENTIFICATION AND MONITORING OF IMMUNOGLOBULIN CHAINS J |
| EP4079848A1 (en) * | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965709A (en) * | 1991-08-14 | 1999-10-12 | Genentech, Inc. | IgE antagonists |
| GB0130228D0 (en) * | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| EP2748197A2 (en) * | 2011-08-26 | 2014-07-02 | Merrimack Pharmaceuticals, Inc. | Tandem fc bispecific antibodies |
-
2013
- 2013-09-20 GB GBGB1316744.0A patent/GB201316744D0/en not_active Ceased
-
2014
- 2014-09-18 KR KR1020167010252A patent/KR20160079784A/ko not_active Withdrawn
- 2014-09-18 EP EP14772310.0A patent/EP3047280A1/en not_active Withdrawn
- 2014-09-18 CA CA2923704A patent/CA2923704A1/en not_active Abandoned
- 2014-09-18 SG SG11201602138VA patent/SG11201602138VA/en unknown
- 2014-09-18 AU AU2014323081A patent/AU2014323081A1/en not_active Abandoned
- 2014-09-18 US US15/023,042 patent/US20160231329A1/en not_active Abandoned
- 2014-09-18 WO PCT/EP2014/069920 patent/WO2015040125A1/en not_active Ceased
- 2014-09-18 JP JP2016515415A patent/JP2016531546A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016531546A5 (OSRAM) | ||
| EA200970694A1 (ru) | ПЭГИЛИРОВАННЫЕ Fab-ФРАГМЕНТЫ АНТИТЕЛ К ПЕПТИДУ Aβ | |
| EA200700136A1 (ru) | Анти-cd154-антитела | |
| AR058955A1 (es) | Inmunglobulinas que se unen a interleuquina 13 | |
| JP2016531546A (ja) | 免疫グロブリン分子試料を分析する方法 | |
| IL186948A0 (en) | Monoclonal antibodies and methods for their use in the detection of cervical disease | |
| RU2012136113A (ru) | Ингибирование axl сигнализации в антиметастатической терапии | |
| PE20090831A1 (es) | Anticuerpo monoclonal | |
| WO2017060322A3 (en) | Ptefb-inhibitor-adc | |
| GEP20115324B (en) | Tweak binding antibodies | |
| AR072897A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| BRPI0816117B8 (pt) | anticorpo monoclonal isolado ou fragmento do mesmo, composiçãofarmacêutica, kit para tratamento de desordens relacionadas com colesterol, e, uso de uma proteína de ligação de antígeno ou de um anticorpo monoclonal ou fragmento do mesmo | |
| RU2011103199A (ru) | Антитела против cdh3, меченные радиоизотопной меткой, и их применение | |
| HRP20090324T1 (hr) | Moduliranje interakcije između hgf beta lanca i c-met | |
| WO2011063003A3 (en) | Peptides and methods for the detection of lyme disease antibodies | |
| JP2019506839A5 (OSRAM) | ||
| Xiao et al. | Identification and quantification of degradations in the Asp–Asp motifs of a recombinant monoclonal antibody | |
| JP7619939B2 (ja) | 原発性免疫不全症、シスチン症、及びウィルソン病に関する新生児スクリーニング | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| PE20230348A1 (es) | Variantes de anticuerpos felinos | |
| JP2014509860A5 (OSRAM) | ||
| US20230194545A1 (en) | Antibodies that specifically bind peptides associated with the primary immunodeficiencies: wiskott-aldrich syndrome and x-linked agammaglobulinemia | |
| WO2006083964A3 (en) | Modified fusion molecules for treatment of allergic disease | |
| WO2004052932A3 (en) | Antibody (“11c7”) anti nogo a and its pharmaceutical use | |
| WO2017118307A1 (zh) | Pcsk9抗体、其抗原结合片段及其医药用途 |